CLINICAL_TRIALS
trial_result
· 2020-05-28
Clinical Trial Update: Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy [Phase 2]
Summary
Phase 2 clinical trial evaluating dupilumab as an adjunct to subcutaneous grass immunotherapy for allergic rhinitis completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regeneron Pharmaceuticals | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED | Results posted: 2020-05-28